Sensei Biotherapeutics (NASDAQ:FTH) CFO Brian Stephenson Purchases 7,803 Shares of Stock

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) CFO Brian Stephenson acquired 7,803 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were bought at an average price of $24.25 per share, with a total value of $189,222.75. Following the transaction, the chief financial officer owned 41,688 shares in the company, valued at $1,010,934. This represents a 23.03% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Sensei Biotherapeutics Trading Down 5.4%

FTH traded down $1.34 during trading on Wednesday, hitting $23.66. The company’s stock had a trading volume of 114,325 shares, compared to its average volume of 89,623. Sensei Biotherapeutics, Inc. has a twelve month low of $6.32 and a twelve month high of $36.76.

Analyst Upgrades and Downgrades

FTH has been the topic of several analyst reports. HC Wainwright assumed coverage on Sensei Biotherapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $60.00 target price on the stock. Weiss Ratings initiated coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. Finally, Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $58.50.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.